Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · Real-Time Price · USD
2.830
+0.040 (1.43%)
Mar 13, 2026, 4:00 PM EDT - Market closed

Protalix BioTherapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Mar '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
2281431307438126
Market Cap Growth
29.90%9.81%76.21%94.49%-69.98%159.30%
Enterprise Value
206.4111.7989.9283.8731.1796.21
Last Close Price
2.831.881.781.370.833.63
PE Ratio
40.9747.0019.78-4.42-1.34-16.50
Forward PE
19.523.94-60.89--
PS Ratio
3.682.671.981.550.992.01
PB Ratio
4.303.303.87-6.93-6.28-4.67
P/TBV Ratio
4.593.534.37-6.24-6.08-3.91
P/FCF Ratio
-19.29-52.64-2.88-3.23-4.72
P/OCF Ratio
-16.44-98.52-2.95-3.68-4.83
EV/Sales Ratio
3.342.091.371.760.811.53
EV/EBITDA Ratio
26.5321.417.72-7.03-1.6123.98
EV/EBIT Ratio
32.4228.548.60-6.44-1.5235.50
EV/FCF Ratio
-15.12-36.45-3.27-2.65-3.60
Debt / Equity Ratio
0.130.090.14-3.04-5.35-0.32
Debt / EBITDA Ratio
1.051.062.26-2.81-1.7316.05
Debt / FCF Ratio
-0.700.75-10.65-1.31-2.85-2.41
Net Debt / Equity Ratio
-0.40-0.68-0.55-1.060.91-0.96
Net Debt / EBITDA Ratio
-2.72-5.61-1.57-0.950.286.44
Net Debt / FCF Ratio
1.81-3.967.41-0.440.47-0.97
Asset Turnover
0.790.680.930.740.541.11
Inventory Turnover
1.241.211.281.131.051.02
Quick Ratio
2.001.471.090.831.280.47
Current Ratio
3.032.341.541.381.860.64
Return on Equity (ROE)
12.82%8.25%55.98%195.61%209.85%32.37%
Return on Assets (ROA)
7.63%3.58%14.35%-20.78%-28.90%4.78%
Return on Invested Capital (ROIC)
25.39%18.56%63.93%-100.63%-209.83%31.07%
Return on Capital Employed (ROCE)
11.78%9.04%33.60%-40.77%-186.45%-40.68%
Earnings Yield
2.37%2.13%5.06%-22.63%-74.55%-6.06%
FCF Yield
-5.14%5.18%-1.90%-34.78%-31.00%-21.21%
Buyback Yield / Dilution
-7.23%-2.54%-19.00%-11.18%-121.93%-36.99%
Updated Nov 13, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q